IDSA journals manuscript review CME program
The Infectious Diseases Society of America offers category 1 CME credit for reviewing manuscripts. Only reviews received on time and judged satisfactory by the Editor(s) responsible for the particular manuscript will be eligible for CME credit. We only provide CME credit to reviewers if they request CME credit at the time they complete their review.
The features that contribute most importantly to the quality of manuscript reviews for the Journal include: adherence to reviewer guidelines, specificity and accuracy, completeness, usefulness of recommendations to both editors and authors, tone, internal consistency, and mindfulness of the needs of our readers and the medical community as a whole.
To prepare a high quality review, the reviewer should consider existing evidence when preparing his or her comments. The reviewer should place the current work in the context of existing evidence in the area, describe the unique contributions of the current work, and comment on any inconsistencies of the current work with previous research in your area.
You will be notified via email if your review of the assigned manuscript was completed on time and if it met our criteria for CME credit.
Statement
The Infectious Diseases Society of America is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. IDSA designates each manuscript review for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians are eligible for up to 3 CME credits for each manuscript review, up to a total of 15 per year.
Objectives
Through the manuscript peer review process for CID, JID, or OFID, you should be able to:
- integrate new discoveries or observations in infectious disease research that can be applied in your work
- use information resources that improve your ability to treat patients or to conduct research in infectious diseases
- identify articles that provide relevant, new data about infectious diseases that could result in additional knowledge
- apply new information that could result in improved healthcare outcomes
Conflicts of Interest
In compliance with ACCME’s Standards for Commercial Support of Continuing Medical Education, anyone in a position to influence content is required to disclose any real or apparent conflicts of interest before participating in a CME-accredited educational activity. IDSA, in collaboration with CID, JID and OFID, identifies and resolves all conflicts of interest prior to manuscript reviews.
|
Name |
Potential Conflicts Declared |
|
Jose Arribas |
Advisory/Consultant Gilead, Viiv, Merck
Honoraria Gilead, Viiv, Merck
Meetings/Travel Support Gilead, Viiv, Merck |
|
Sara Bares |
Expert Testimony Gilead Sciences |
|
Taison Bell |
Nothing to disclose |
|
Christina Coyle |
Nothing to disclose |
|
Emily Heil Dante |
Nothing to disclose |
|
Jason Gallagher |
Advisory/Consultant GSK, Astellas, Meitheal, Shionogi, Merck, Pfizer, Invivyd, Abbvie
Honoraria Abbvie Shionogi
Research Grants/Contracts Merck |
|
Kim Hanson |
Advisory/Consultant Devle Bio, Karius, Anvil Diagnostics |
|
Vivek Jain |
Nothing to disclose |
|
Colleen Kraft |
Advisory/Consultant Ferring/Rebyota, Vedanta, Rebiotix
Patent/Copyright/License Fecal transplant processing patent
Research Grants/Contracts Kaiser Permanente, Armata Pharmaceuticals, Ferring Pharmaceuticals, Delve Bio |
|
Susanna Naggie |
Advisory/Consultant Astra Zeneca
Stocks/Bonds Vir Biotechnology |
|
Ruvandhi Nathavitharana |
Nothing to disclose |
|
Jeremy Nel |
Honoraria Abbvie
Research Grants/Contracts Novo Nordisk |
|
Luis Ostrosky-Zeichner |
Advisory/Consultant Knight/Biotoscana, Eurofins Viracor, Octapharma, Gilead, F2G, Stendhal, Pfizer, Incyte, CSL, PhD Femenine, Kapłan, Melinta, Meiji, Terranova, Karius, GSK, Basilea, Scynexis, Pulmocide
Research Grants/Contracts Basilea, Pulmocide, Scynexis, Pfizer, Eurofins Viracor, IMMY
Stocks/Bonds Doximity |
|
Jean-Jacques Parienti |
Advisory/Consulting Gilead, Merck, Viiv
Honoraria Gilead, Merck, Viiv
Meetings/Travel Support Merck, Gilead
Research Grants/Contracts Gilead, Merck |
|
Robin Patel |
Advisory/Consultant PhAST, Iterum Therapeutics, DEEPULL DIAGNOSTICS, Claryx, Inc., S.L., Nostics, bioMérieux, CARB-X
Patents Patents on Bordetella pertussis/parapertussis PCR, device/method for sonication, PET imaging of bacterial infection with a PET probe (filed), anti-biofilm substance
Research Grants/Contracts MicuRx Pharmaceuticals, ImmuCell |
|
David Pegues |
Advisory/Consultant Pfizer, NIDCR/Rho, Alexion/Syneos |
|
Federico Perez |
Research Grants/Contracts Merck |
|
Adam Ratner |
Nothing to disclose |
|
Raymond Razonable |
Advisory/Consultant Novartis, Allovir
Research Grants/Contracts Gilead |
|
Chanu Rhee |
Nothing to disclose |
|
Nadine Rouphael |
Advisory/Consultant Moderna, Pfizer, Sanofi, GSK, Sequirus, Krog, ICON, Emmes (EMMES), CyanVac, Immunon
Meetings/Travel Support Sanofi, Moderna, Pfizer
Research Grants/Contracts Vaccine Company, Cocrystal, Sanofi, Pfizer and Merck |
|
Michael Rybak |
Advisory/Consultant Innovia Therapeutics
Honoraria Abbvie
Research Grants/Contracts Paratek Pharmaceuticals |
|
Paul Sax |
Advisory/Consultant Gilead, Merck, Shionogi, Viiv
Research Grants/Contracts Gilead, Viiv |
|
Ilan Schwartz |
Advisory/Consultant Pulmocide Inc. |
|
Maunank Shah |
Other Interests Patent
|
|
Emmanuel (Chip) Walter |
Advisory/Consultant Pfizer, Seqirus, Vaxcyte, Shionogi, Emmes
Meetings/Travel Support Pfizer, Seqirus, Vaxcyte
Research Grants/Contracts Pfizer, Moderna, Seqirus, Najit, Clinetic |
|
Name |
Potential Conflicts Declared |
|
David Andes |
Advisory/Consultant
|
|
Kara Chew |
Consulting In-Kind Contributions
|
|
Helen Chu |
Honoraria Vir, Roche
|
|
Neil Clancy |
Advisory/Consultant |
|
Julio Croda |
Advisory/Consultant
|
|
Sara Gianella Weibel |
Nothing to declare |
|
Audrey Odom John |
Advisory/Consultant In-Kind Contributions Patents
|
|
Adam Lauring |
Advisory/Consultant Roche
|
|
Daniel Leung |
Patents Analyzing Nucleic Acids from Solid and Semi-Solid Samples Using Digital Microfluidics
|
|
Joseph Lewnard |
Advisory/Consultant
|
|
Jonathan Li |
Advisory/Consultant Research Grants/Contracts
|
|
Anita McElroy |
Nothing to declare |
|
Roger Paredes |
Advisory/Consultant Honoraria Meetings/Travel Support Patents Research Grants/Contracts
|
|
Anne Piantadosi |
Advisory/Consultant Research Grants/Contracts
|
|
Cindy Sears |
Advisory/Consultant Patents Research Grants/Contracts
|
|
Irini Sereti |
Patent Monoclonal anti-lymphocyte antibody (in development)
|
|
Kathryn Stephenson |
Advisory/Consultant Imunon, Bavarian Nordic |
|
Anne-Catrin Uhlemann |
Nothing to declare
|
|
Name |
Potential Conflicts Declared |
|
Sam Aitken |
Advisory/Consultant Alembic, Meitheal, bioVersys, Merck, GSK, Shionogi, Guidepoint Global Advisors
Honoraria Shionogi |
|
Nancie Archin |
Honoraria Gilead |
|
Sandra Arnold |
Research Grants/Contracts Pfizer |
|
John Baddley |
Advisory/Consultant Pulmocide, Eli Lilly, Novo Nordisk, Amgen |
|
Roger Bedimo |
Advisory/Consulting Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc, Shionogi, Janssen Pharmaceuticals |
|
James (Brad) Cutrell |
Advisory/Consultant Deepull and MDC Associates |
|
Christine Durand |
Advisory/Consultant Gilead
In-Kind Contributions Gilead |
|
Edward Gardner |
Research Grants/Contracts Gilead, Viiv |
|
Martin Hoenigl |
Advisory/Consultant Shionogi, Mundipharma, PharmaHoldings, Gilead, Basilea, Elion
Honoraria Mundipharma, Scynexis, Shionogi, Gilead, Astra Zeneca, Medical Dialogue, medUpdate, Onconovium, Viatris, Janssen
In-Kind Contributions Karius, Cape Cod Diagnostics, Mycomeia
Research Grants/Contracts FWF, ECMM, Gilead, Melinta, Mundipharma, GSK, Pfizer, Shionogi, Basilea, IMMY, MSD, Pulmocide, Cape Cod Diagnostics, Biomerieux |
|
Hannah Imlay |
Nothing to disclose |
|
Regina LaRocque |
Nothing to disclose |
|
Monica Mahoney |
Advisory/Consultant CSL Seqirus, BD Biosciences, Cidara, GSK |
|
Jen Manne-Goehler |
Nothing to disclose |
|
Laura Marks |
Research Grants/Contracts Gilead |
|
Carlos Mejia-Chew |
Nothing to disclose |
|
Jeniel Nett |
Nothing to disclose |
|
Obinna Nnedu |
Nothing to disclose |
|
Dylan Pillai |
Patents Lyophilization method for LAMP testing |
|
Carlos Seas |
Nothing to disclose |
|
William Short |
Advisory/Consultant Viiv, Gilead
Honoraria Viiv |
|
Andrej Spec |
Advisory/Consultant Revimmune, MSG, F2G, Scynexis
Honoraria Astellas, IMMY
Research Grants/Contracts Astellas |
|
Francois Venter |
Research Grants/Contracts MSD, Gilead, Novo
Honoraria ViiV, Mylan/Viatris, MSD, Adcock-Ingram, Aspen, Abbott, Roche, Sanofi, Boehringer Ingelheim, Thermo-Fischer
In-Kind Contributions MSD |
|
Laila Woc-Colburn |
Nothing to disclose |
|
Darcy Wooten |
Nothing to disclose |
|
Christina Yek |
Nothing to disclose |